Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033

被引：7

作者：

Zhou, C. ^{[1
]}

Feng, J. ^{[2
]}

Ma, S. ^{[3
]}

Chen, H. ^{[4
]}

Ma, Z. ^{[5
]}

Huang, C. ^{[6
]}

Zhang, L. ^{[7
]}

He, J. ^{[8
]}

Wang, C. ^{[9
]}

Zhou, J. ^{[10
]}

Danchaivijtr, P. ^{[11
]}

Huang, H-C. ^{[12
]}

Vynnychenko, I. O. ^{[13
]}

Wang, K. ^{[14
]}

Orlandi, F. ^{[15
]}

Sriuranpong, V. ^{[16
]}

Li, B. ^{[17
]}

Ge, J. ^{[18
]}

Dang, T. ^{[19
]}

机构：

[1] Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China

[2] Jiangsu Canc Hosp, Oncol, Nanjing, Jiangsu, Peoples R China

[3] Hangzhou First Peoples Hosp, Oncol, Hangzhou, Zhejiang, Peoples R China

[4] Guangdong Prov Peoples Hosp, Oncol, Guangzhou, Guangdong, Peoples R China

[5] Henan Canc Hosp, Med Oncol, Zhengzhou, Henan, Peoples R China

[6] Fujian Prov Canc Hosp, Oncol, Fuzhou, Fujian, Peoples R China

[7] Sun Yat Sen Univ, Oncol, Guangzhou, Guangdong, Peoples R China

[8] Guangzhou Med Univ, Affiliated Hosp 1, Thorac Surg, Guangzhou, Guangdong, Peoples R China

[9] Tianjin Med Univ Canc Inst & Hosp, Med Oncol, Tianjin, Peoples R China

[10] Zhejiang Univ, Affiliated Hosp 1, Med Oncol, Hangzhou, Zhejiang, Peoples R China

[11] Siriraj Piyamaharajkarun Hosp, Med Oncol, Bangkok, Thailand

[12] Chang Gung Med Fdn, Med Oncol, Taoyuan, Taiwan

[13] Sumy State Univ, Med Oncol, Sumy, Ukraine

[14] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Med Oncol, Hangzhou, Zhejiang, Peoples R China

[15] Orlandi Oncol, Med Oncol, Providencia, Region Metropol, Chile

[16] King Chulalongkorn Mem Hosp, Med Oncol, Bangkok, Thailand

[17] MSD China, Oncol, Beijing, Peoples R China

[18] MSD China, Oncol, Shanghai, Peoples R China

[19] Merck & Co Inc, Oncol, Kenilworth, NJ USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1576

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1262P

引用

页码：S816 / S816

页数：1